News
Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA ...
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...
In honor of the annual World Lung Cancer Day commemoration on Aug. | In honor of the annual World Lung Cancer Day ...
Merz Aesthetics has revamped its sales and marketing leadership, promoting an employee and hiring a vice president from GSK ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...
The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the European Union may have not been the ideal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results